Most NDAs Don’t Fail on Science. They Fail on Strategy.
In pharma, we love to talk about molecules—mechanisms, trial design, endpoints, and the elegance of the data. But anyone who’s shepherded an NDA knows the uncomfortable truth: the submission is …

Two clocks. One drug. And the real deadline isn’t what you think.
In pharma, timelines are never just timelines—they’re leverage.
A drug doesn’t “face competition” on a single date. It faces it when two separate clocks run out—often on different days, …

Small Molecules vs. Biologics: The Real “Liftoff” Strategy for Generics vs. Biosimilars
Drug patent strategy is often discussed like a checklist: file early, extend where possible, litigate when necessary. But the market reality is more nuanced—and the…

Biopharma is entering a new era of “tender-first” commercialization—especially as blockbuster drugs approach loss of exclusivity (LOE). For commercial vendors selling tender strategy consulting across EU markets, the opportunity is real. But so is the …

Pharma doesn’t always need a new molecule to make billions. It needs a new story.
For years, the industry’s headline act has been “new drugs.” But the quieter, more lucrative plot twist is happening with mature medicines—old molecules repackaged, re-po…

Biopharma is entering a new kind of arms race: not just against competitors, but against time.
As patents near expiration, the industry doesn’t simply face generic entry—it faces a cascading loss of exclusivity that can compress revenues, destabilize f…

One-shot strategy: how to pick the right drug patent for maximum term-extension value
In pharma, timing is everything—but so is which clock you’re trying to extend.
For companies navigating patent cliffs, the difference between “some protection” and “r…

Designing Around Drug Patents: The Quiet Skill That Separates Fast Followers From Costly Litigators
In pharma, the hardest part isn’t always inventing—it’s navigating. And nowhere is that more true than in the “design-around” phase, where teams try to …

Drug patent litigation isn’t just about molecules—it’s about design choices.
In pharma, “design around” sounds like a strategy. In practice, it’s a discipline: a way to translate patent language into formulation decisions, development timelines, and …

Pharma has a $300 billion problem—and it’s not just about patents. It’s about time.
In the U.S., the patent system doesn’t simply grant rights; it grants a clock. And for brand drugmakers, that clock can mean the difference between funding next-generat…